{"url_path":"/sec/gyre/8-k/2026-06-16/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-16","source_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-025324-index.html","accession_number":"0001140361-26-025324","cik":"0001124105","ticker":"GYRE","issuer_name":"GYRE THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-025324-index.html","primary_entity_key":"0001124105","primary_entity_name":"GYRE THERAPEUTICS, INC."},"word_count":353,"has_tables":true,"body_markdown":"Item 5.07.\n\nSubmission of Matters to a Vote of Security Holders.\n\n \n\nOn June 10, 2026, Gyre Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”).  As of the close of business on April 16,\n2026, the record date for the Annual Meeting, there were 96,994,001 shares of common stock entitled to vote at the meeting.\n\n \n\nAt the Annual Meeting, each of the Company’s director nominees was elected and the other proposals voted on were approved.  The proposals are described in the Company’s\ndefinitive proxy statement filed with the U.S. Securities and Exchange Commission on April 27, 2026.  The final voting results are set forth below.\n\n \n\nProposal 1: Election of Directors\n\n \n\nThe following Class II director nominees were elected to serve until the 2029 Annual Meeting of Stockholders based upon the following votes:\n\n \n\nNominee\n\nVotes\n\nFor\n\nVotes\n\nWithheld\n\nBroker\n\nNon-Votes\n\n•          David M. Epstein, Ph.D.\n\n70,160,332\n\n354,109\n\n1,985,197\n\n•          Dan Weng, M.D.\n\n70,483,425\n\n31,016\n\n1,985,197\n\nProposal 2: Non-Binding Advisory Vote on Executive Compensation\n\n \n\nThe compensation of the Company’s named executive officers was approved, on a non-binding, advisory basis, as follows:\n\n \n\nVotes\n\nFor\n\nVotes\n\nAgainst\n\nAbstentions\n\nBroker\n\nNon-Votes\n\n70,478,374\n\n34,907\n\n1,160\n\n1,985,197\n\nProposal 3: Ratification of Independent Auditor\n\n \n\nThe appointment of Grant Thornton Zhitong Certified Public Accountants LLP as the Company’s independent registered public accounting firm for the year ending December 31,\n2026 was ratified as follows:\n\n \n\nVotes\n\nFor\n\nVotes\n\nAgainst\n\nAbstentions\n\nBroker\n\nNon-Votes\n\n72,487,596\n\n11,626\n\n416\n\n0\n\nProposal 4: Approval of Conversion of Series B Preferred Stock\n\n \n\nThe issuance of shares of the Company’s common stock, par value $0.001 per share, upon conversion of the Company’s Series B Convertible Preferred Stock, par value $0.001\nper share, was approved, in accordance with Nasdaq Listing Rule 5635(a), as follows:\n\n \n\nVotes\n\nFor\n\nVotes\n\nAgainst\n\nAbstentions\n\nBroker\n\nNon-Votes\n\n70,497,125\n\n16,031\n\n1,285\n\n1,985,197\n\n2\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed\non its behalf by the undersigned hereunto duly authorized.\n\nGYRE THERAPEUTICS, INC.\n\nDate: June 16, 2026\n\nBy:\n\n/s/ Thomas Eastling\n\nName:\n\nThomas Eastling\n\nTitle:\n\nChief Financial Officer\n\n3"}